CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma

In the three patients included in a phase I clinical trial (NCT01421524), we report the immunomodulatory effects and efficacy of CC-122, a novel pleiotropic pathway modifier compound originally developed for broad diffuse large B-cell lymphoma (DLBCL). The chemical structure of CC-122 includes the g...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology
Hauptverfasser: Cubillos-Zapata, Carolina, Cordoba, Raúl, Avendaño-Ortiz, José, Arribas-Jiménez, Cristina, Hernández-Jiménez, Enrique, Toledano, Víctor, Villaescusa, Teresa, Moreno, Víctor, López-Collazo, Eduardo
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2016
Schlagworte:
Brief Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5325046/
https://ncbi.nlm.nih.gov/pubmed/28255524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1231290
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge